WASHINGTON, D.C. (LifeSiteNews) — Three major abortion pill manufacturers are putting women at risk by operating with little-to-no oversight in how the pills are actually manufactured or prescribed, according to a new report led by U.S. Sen. Bill Cassidy (R-LA).
The Daily Signal reports that the review by the Senate Health, Education, Labor and Pensions (HELP) Committee, which Cassidy chairs, examined Mifeprex producer Danco Laboratories, generic mifepristone producer GenBioPro, and Evita Solutions, the company behind the most recent generic version of the abortion pill.
The companies provided the committee with little information about their practices, but the committee found Danco’s pills are completed at an unknown location “elsewhere in Europe,” while GenBioPro and Evita produce their pills in India. The lack of transparency about where exactly the pills are manufactured also means the standards under which they are manufactured cannot be ascertained.
The report further asserts that none of the companies take steps to ensure that their pills are only dispensed in ways that comply with the U.S. Food and Drug Administration’s (FDA) Mifepristone Risk Evaluation and Mitigation Strategy program, the waiver of which starting under the Biden administration gave rise to the mail-order abortion pill business and added risk of self-administering chemical abortions with no medical professionals present, or other remaining health and safety regulations.
“An example of this is the website Aid Access, which allows individuals to order mifepristone without any medical oversight or direct patient-prescriber relationship,” the HELP committee says. It goes on to note that “Danco and GenBioPro told the Committee that they have no role in ensuring that doctors and other health care providers who prescribe chemical abortion drugs maintain compliance with the FDA requirements, implying that the onus is on the prescribers to police themselves. Given the lack of oversight, there are concerns that these sponsors are disregarding the safety risks of chemical abortions and either overtly or tacitly allowing their products to be sold to bad actors who seek to exploit women for profit.”
“Abortion drug companies are putting mothers at risk through their failure to properly oversee the prescription and distribution of their products. We are seeing that the explosion in online sales of chemical abortion drugs has opened the door to coercion and abuse of women,” Cassidy declared. “FDA and the sponsors of these drugs have a responsibility to the American people to crack down on these prescribers that violate the prescribing requirements and reinstate the safeguards that keep mothers and babies safe.”
Mail-order pills have become the abortion lobby’s most potent tool for circumventing these laws and preserving abortion without Roe v. Wade, despite risks evidenced by an April 2025 analysis by the Ethics and Public Policy Center, which concluded that almost 11 percent of women suffer sepsis, infection, hemorrhaging, or other major conditions after taking mifepristone, according to insurance data, plus similar findings by the Restoration of America Foundation, as part of a “growing body of evidence indicating that the health risks associated with mifepristone abortions are severe, widespread, and significantly underreported.”
Yet when running to return to the White House in 2024, President Donald Trump declared he would not reverse those changes. In May 2025, the Trump administration promised to review the safety data on abortion pills, then going largely silent until a June update that the review was finally underway and slated to be completed after the fall midterm elections. The state of Louisiana has led the charge to force a change with a federal lawsuit, but the Trump administration has urged the courts to at least temporarily reject it until the review is complete.
Pro-lifers are currently waiting to see whether encouraging comments by Trump’s new Attorney General Todd Blanche plus a presumptive new FDA commissioner in Dr. Heidi Overton will reflect a change in policy.